Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 115Myelodysplastic Syndromes 109Precursor Cell Lymphoblastic Leukemia-Lymphoma 95Leukemia 74Hodgkin Disease 73Leukemia, Lymphocytic, Chronic, B-Cell 72Multiple Myeloma 71Lymphoma, Non-Hodgkin 71Lymphoma 66Myeloproliferative Disorders 54Graft vs Host Disease 50Lymphoma, Follicular 49Lymphoma, Mantle-Cell 47Leukemia, Myeloid, Accelerated Phase 47Lymphoma, Large B-Cell, Diffuse 46Congenital Abnormalities 46Leukemia, Myelomonocytic, Chronic 44Lymphoma, B-Cell, Marginal Zone 43Hematologic Neoplasms 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 42Leukemia, Myeloid, Chronic-Phase 41Burkitt Lymphoma 40Primary Myelofibrosis 39Blast Crisis 38Neoplasms, Plasma Cell 37Lymphoma, Large-Cell, Immunoblastic 32Waldenstrom Macroglobulinemia 25Myelodysplastic-Myeloproliferative Diseases 24Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 24Lymphoma, T-Cell, Cutaneous 23

Interventions

Methotrexate 21Ifosfamide 21Cyclophosphamide 19Doxorubicin 17Cisplatin 14Filgrastim 13Gemcitabine 12Etoposide 11Leucovorin 9apatinib 8fludarabine 7glucarpidase 6Vincristine 6Temozolomide 6Radiotherapy 6Nivolumab 6Neoadjuvant Therapy 6Drug Therapy 6Carboplatin 6regorafenib 5cabozantinib 5Zoledronic Acid 5Topotecan 5Mesna 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Docetaxel 5pembrolizumab 4pegfilgrastim 4camrelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Osteosarcoma × Tacrolimus × Clear all
NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡